18 November 2023 in Chemical Engineering Journal
26 February 2026 in Nano Letters
Most hospital-acquired infections originate from bacterial biofilms on implantable devices, where the extracellular polymeric substance (EPS) matrix protects microbes and promotes multidrug resistance (MDR). Preventing biofilm initiation, particularly bacterial adhesion and proliferation, offers an effective strategy to combat device-associated infections. However, developing biocompatible materials that combine antimicrobial and antiadhesive functions remains a challenge. Herein, we present a strategy to engineer antibiofilm hydrogels by incorporating antimicrobial peptoids (ampetoids) into a gelatin-based matrix with controlled supramolecular organization. By tuning the stoichiometric ratio between thiol-functionalized ampetoids and norbornene groups in the matrix, we controlled peptoid nanostructure within the hydrogel, where suppression of peptoid self-assembly proved critical for balancing antimicrobial activity, antiadhesive properties, and cytocompatibility. This molecular-level control enabled the hydrogels to inhibit biofilm formation by S. aureus and P. aeruginosa. These results highlight regulation of peptoid self-assembly within hydrogels as a promising approach for designing multifunctional antibiofilm coatings for contamination-prone medical devices.
19 September 2025 in Journal of Medicinal Chemistry
23 October 2024 in npj Parkinson's Disease
Cereblon (CRBN) is a substrate recruiter for CRL4CRBN E3 ubiquitin ligase system playing a plethora of pivotal roles for biological systems. Here, we identified DNAJB1 (DJ1) as endogenous substrate of CRBN and report how CRBN influences the aggregation and toxicity of alpha-synuclein (α-SYN) via modulation of DJ1. CRBN interferes with molecular activities of DJ1 in vitro, in cells, and in vivo resulting in a reduced disaggregation of α-SYN fibrils, increased formation of preformed fibrils (PFFs) of α-SYN, and high susceptibility of mice to MPTP and PFF-induced neurotoxicity. Depletion of Crbn improves the behavioral and biochemical responses of mice towards neurotoxic insult. Finally, we designed a peptide inhibitor to inhibit the recruitment of DJ1 to CRBN for ubiquitination, resulting in an enhanced supply of DJ1 to counteract the toxicity of aggregated α-SYN. Our data has important implications for development of CRBN-targeting therapies that could prevent or delay progression of neurodegenerative synucleinopathy.